Skip to Accessibility Tools Skip to Content Skip to Footer

Ajovy™ (fremanezumab-vfrm)

Ajovy is a calcitonin-gene-related peptide (CGRP) blocker for the preventive treatment of migraine in adults. Ajovy is manufactured by Teva Pharmaceuticals and is an injectable medication.1

What is the ingredient in Ajovy?

The active ingredient in Ajovy is fremanezumab, a monoclonal antibody.1

How does Ajovy work?

Ajovy is a monoclonal antibody that targets CGRP. Like antibodies that are created by the body to target specific invaders, monoclonal antibodies are created in a laboratory to attach to specific proteins. Ajovy attaches to the CGRP peptide ligand, and blocks its binding to the receptor. The CGRP protein is involved in the dilation of veins (vasodilation) and in the sensory nervous system, both of which are impacted by migraine.2 Research has found that during a migraine attack, CGRP levels are increased. By blocking the protein’s ability to connect with the receptor, Ajovy may reduce the frequency or severity of migraine attacks.1

What are the possible side effects of Ajovy?

The most common side effects experienced by patients receiving Ajovy in clinical trials were injection site reactions, such as redness or pain at the site of the injection. In some people, Ajovy caused a hypersensitivity reaction (severe allergic reaction), which may appear as a rash, itching, or hives. Ajovy should be discontinued if an allergic reaction occurs.1

Things to know about Ajovy

Ajovy has not been studied in women who are pregnant or breastfeeding, and it is not known if Ajovy may cause any risks to unborn or breastfeeding infants.1

Ajovy has not been evaluated in children and is currently only approved for use in adults.1

Dosing information

Ajovy is available in a pre-filled syringe that is given subcutaneously (under the skin). It may be administered by a healthcare professional, the patient, or a caregiver. Two dosing options are available: 225 mg given monthly or 675 mg given every 3 months (quarterly).1

For more information, read the full prescribing information for Ajovy.

Written by: Emily Downward | Last reviewed: August 2019
  1. Ajovy prescribing information. Available at Accessed 9/14/18.
  2. Bell J. Teva says CGRP drug could gain approval by mid-September. Biopharma Dive. Available at Accessed 9/14/18.